LianBio (LIANY) intrinsic value & 10-year financials
LianBio (LIANY) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.05
- Market cap
- $5.5M
- Revenue (FY2022)
- —
- ROIC (10-yr avg)
- 35.7%
- Free cash flow (FY2022)
- -$101.0M
LIANY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | — | -$110.3M | -$1.02 | -$101.0M | — | -80.1% |
| FY2021 | — | -$196.3M | -$1.90 | -$164.9M | — | 152.3% |
| FY2020 | — | -$139.6M | -$1.29 | -$99.0M | — | 35.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LianBio revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LianBio has historically struggled to out-earn its cost of capital, averaging just -14.5% ROIC.
LianBio capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LianBio is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.